AI and the Big Data paradigm – big ambitions in novel drug discovery - AI and the Big Data paradigm – big ambitions in novel drug discovery

Over the past few decades, data generation has veritably exploded. However, the'Big Data paradigm' is not so much concerned with the volume of that data, but how businesses and, indeed, industries can derive meaningful insights from what has become a glut of information. With the currently popular approach to artificial intelligence (AI) focussing on the Big Data paradigm, also, pharmaphorum spoke with Adityo Prakash, CEO of Verseon, about the whys and wherefores, delving deeper into the processes for dealing with the current mountain of data and how it can be generated, as well as the purposes for which it can be dealt with constructively, and efficiently. "The fundamental underlying assumption is that an enormous amount of data is available to teach an AI programme how to handle the problem at hand," Prakash began. However, he explained, "the number of known examples to train AI is at least many thousands of times larger than the number of variables or features to be tracked."